Last reviewed · How we verify

NCT06828107: SENSE-007

A Study to Evaluate the SENSE Device's Ability to Detect TBI

Recruiting now Last updated 25 November 2025
What this trial tests

trial testing SENSE device in Traumatic Brain Injury in 150 participants. Currently enrolling.

Timeline
11 July 2025
Primary endpoint
30 May 2026
30 June 2026

Quick facts

Lead sponsorSense Diagnostics, LLC
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment150
Start date11 July 2025
Primary completion30 May 2026
Estimated completion30 June 2026
Sites6 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

Sense Diagnostics, LLC

Who can join

22 and older, any sex, with Traumatic Brain Injury. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study population will consist of 3 mutually-exclusive sets of patients and subjects: * TBI patients with intracranial bleeding * TBI patients without intracranial bleeding * Control subjects with normal brain health. Research subjects ages 22 and older will be enrolled. All TBI patients must be monitored with the SENSE Device within 6 hours of a diagnostic head CT scan ordered by a treating clinician and within 24 hours of injury.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Traumatic Brain Injury

Currently open trials in the same condition.

Other Sense Diagnostics, LLC trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06828107.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing